{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-072330","form_type":"8-K","ticker":"MOVE","cik":"0001734750","company_name":"Corvex, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.924420+00:00","generated_at":"2026-06-21T20:43:31.208295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Movano Health reports Q3 net loss of $8.6M; progress on FDA submission and beta programs","bullets":["Net loss of $8.6M ($0.26 diluted EPS) vs $5.2M ($0.16) in Q3 2021; no revenue.","Cash and short-term investments $16.8M at Sept 30, down from $33.6M at Dec 31, 2021.","Raised $1.9M via ATM facility in Q3; 33.5M shares outstanding.","Plans to file for FDA clearance for heart rate and SpO2 in early 2023 after pivotal hypoxia study.","Beta programs underway with Novant Health, Stanford, and two other partners; product launch expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-072330","json":"https://secwatch.observer/filing/0001213900-22-072330.json","markdown":"https://secwatch.observer/filing/0001213900-22-072330.md","text":"https://secwatch.observer/filing/0001213900-22-072330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/0001213900-22-072330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/ea168495-8k_movanoinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:43:31.208295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20ae645b7d54a81025c0bb4659c7a8024943bd7c","claim":"Corvex, Inc. reported three months ending September 30, 2022 results: net income $8.6 million, EPS $(0.26) per basic and diluted share.","evidence_excerpt":"Movano Health reported a net loss attributable to common stockholders of $8.6 million, or a loss of $(0.26) per basic and diluted share, in the third quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/0001213900-22-072330-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ending September 30, 2022"},{"label":"Net income","value":"$8.6 million"},{"label":"EPS","value":"$(0.26) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}